Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > FY2020 Drug Pricing Reform
FY2020 Drug Pricing Reform
-
Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
-
Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
December 16, 2019
-
Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
-
Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
-
US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
-
Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
-
Average NHI-Market Price Gap at 8.0%, Suspected Bid-Rigging Data Excluded: Chuikyo
December 4, 2019
-
MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
-
Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
-
MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
-
MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
-
Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
-
No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
-
MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
-
MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
-
MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
-
Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
-
MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process
November 12, 2019
-
Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
-
Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…